Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.

Diagnostic pathology - 11 May 2020

Mei Ping, Freitag C Eric, Wei Lai, Zhang Yunxiang, Parwani Anil V, Li Zaibo

Abstract excerpt

BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emerging as a biomarker to predict clinical response to immunotherapy in melanoma and non-small cell lung cancer patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Cohort Studies

Share to DNA Damage

Share to DNA Repair

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32393302
DOI: 10.1186/s13000-020-00971-7
PMCID: PMC7212599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.PMID 32393302Read ↗

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

Prevalence and mutational determinants of high tumor mutation burden in breast cancer.Semantic proximity Read ↗

Prevalence and mutational determinants of high tumor mutation burden in breast cancerSemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

Correlate tumor mutation burden with immune signatures in human cancersSemantic proximity Read ↗

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read ↗

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast CancerSemantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.